公开(公告)号：US12131801B2

公开(公告)日：2024-10-29

申请号：US18513348

申请日：2023-11-17

Applicant: Genentech, Inc. ,  Simons Foundation ,  New York University

Inventor： Vladimir Gligorijevic ,  Richard Bonneau ,  Kyunghyun Cho

IPC: G01N33/48 ,  G16B15/00 ,  G16B30/20

CPC classification number: G16B15/00 ,  G16B30/20

Abstract: A protein design system includes one or more processors configured to modify, by a modifier, an input sequence corresponding to a protein, the input sequence comprising a data structure indicating a plurality of amino acid residues of the protein; map, by an encoder, the modified sequence to a latent space; predict, by a length predictor, a length difference between the mapped sequence and a target sequence based on at least one target function of the target sequence; identify, by a function classifier, at least one sequence function of the modified sequence; transform, by a length transformer, the modified sequence based on the length difference and the at least one sequence function; and generate, by a decoder, a candidate for the target sequence based on the transformed sequence.

公开(公告)号：US20240352136A1

公开(公告)日：2024-10-24

申请号：US18687561

申请日：2022-09-02

Applicant: Hoffmann-La Roche Inc. ,  Genentech, Inc.

Inventor： Maria Amann ,  Laurène Pousse ,  Christophe Boetsch ,  Martin Weisser ,  Theresa Kolben ,  Vaios Karanikas ,  Jan Eckmann ,  Bruno Carneiro de Medeiros

IPC: C07K16/28 ,  A61K31/496 ,  A61K31/706 ,  A61K39/395

CPC classification number: C07K16/2866 ,  A61K31/496 ,  A61K31/706 ,  A61K39/3955 ,  C07K2317/35 ,  C07K2317/40 ,  C07K2317/732

Abstract: The present invention relates to anti-CD-25 antibodies for use in the treatment of acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL).

公开(公告)号：US12115015B2

公开(公告)日：2024-10-15

申请号：US17473495

申请日：2021-09-13

Applicant: GENENTECH, INC.

Inventor： Nils Gustav Thomas Bengtsson ,  Richard Alan Duray Carano ,  Alexander James Stephen Champion de Crespigny ,  Jill Osborn Fredrickson ,  Mohamed Skander Jemaa

IPC: A61B6/00 ,  G06N3/02 ,  G06T7/11 ,  G06T7/174 ,  G16H10/20 ,  G16H30/20 ,  G16H30/40 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50

CPC classification number: A61B6/5217 ,  A61B6/5235 ,  A61B6/5247 ,  G06N3/02 ,  G06T7/11 ,  G06T7/174 ,  G16H10/20 ,  G16H30/20 ,  G16H30/40 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G06T2207/10088 ,  G06T2207/10104 ,  G06T2207/20016 ,  G06T2207/20084 ,  G06T2207/30096 ,  G06T2207/30242

Abstract: The present disclosure relates to techniques for segmenting tumors with positron emission tomography (PET) using deep convolutional neural networks for image and lesion metabolism analysis. Particularly, aspects of the present disclosure are directed to obtaining a PET scans and computerized tomography (CT) or magnetic resonance imaging (MRI) scans for a subject, preprocessing the PET scans and the CT or MRI scans to generate standardized images, generating two-dimensional segmentation masks, using two-dimensional segmentation models implemented as part of a convolutional neural network architecture that takes as input the standardized images, generating three-dimensional segmentation masks, using three-dimensional segmentation models implemented as part of the convolutional neural network architecture that takes as input patches of image data associated with segments from the two-dimensional segmentation mask, and generating a final imaged mask by combining information from the two-dimensional segmentation masks and the three-dimensional segmentation masks.

公开(公告)号：US20240339191A1

公开(公告)日：2024-10-10

申请号：US18744107

申请日：2024-06-14

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Yusuke Alexander KIKUCHI ,  Ales NEUBERT ,  Carlos Quezada RUIZ ,  Jian DAI

IPC: G16H20/17 ,  A61B3/00 ,  A61B3/10 ,  A61B3/12 ,  G16H50/30

CPC classification number: G16H20/17 ,  A61B3/0025 ,  A61B3/102 ,  A61B3/1225 ,  G16H50/30

Abstract: A method and system for predicting a selected treatment regimen for a subject. Baseline data for a subject diagnosed with neovascular age-related macular degeneration (nAMD) is received. A plurality of predictor inputs is formed for an outcome predictor using the baseline data and regimen data for a plurality of treatment regimens. The plurality of predictor inputs comprises a different predictor input for each of the plurality of treatment regimens. A plurality of treatment scores is generated for the plurality of treatment regimens via the set of outcome predictor using the plurality of predictor inputs. One of the plurality of treatment regimens is selected as a selected treatment regimen for the subject based on the plurality of treatment scores.

公开(公告)号：US20240338823A1

公开(公告)日：2024-10-10

申请号：US18744197

申请日：2024-06-14

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Fethallah BENMANSOUR ,  Jelena NOVOSEL ,  Jian DAI ,  Daniela Ferrara CAVALCANTI

IPC: G06T7/00

CPC classification number: G06T7/0012 ,  G06T2207/20081 ,  G06T2207/30041

Abstract: A method and system for detecting a presence of comorbid ocular conditions. Input data that includes imaging data for an eye of a subject is received. A score that indicates whether a presence of a plurality of comorbid ocular conditions is detected is generated in the eye of the subject using a deep learning model and the input data. A comorbidity output is generated based on the score. The comorbidity score may be a classification indicating whether the presence of the plurality of comorbid ocular conditions is detected.

公开(公告)号：US12090211B2

公开(公告)日：2024-09-17

申请号：US17990988

申请日：2022-11-21

Applicant: Genentech, Inc.

Inventor： Thomas Pillow ,  Peter Dragovich

IPC: A61K47/68 ,  A61K47/65 ,  C07K16/22 ,  C07K16/28

CPC classification number: A61K47/6803 ,  A61K47/65 ,  A61K47/6889 ,  C07K16/22 ,  C07K16/2863

Abstract: The subject matter described herein is directed to methods of preparing certain antibody-drug conjugates (ADCs) wherein the antibody is linked to the drug through a linker, wherein the drug contains a heteroaryl group having a secondary nitrogen, and the linker is attached to the drug via the secondary nitrogen. The resulting conjugates are useful in treating various diseases and conditions.

公开(公告)号：US20240300974A1

公开(公告)日：2024-09-12

申请号：US18516014

申请日：2023-11-21

Applicant: Genentech, Inc.

Inventor： Snahel PATEL ,  Gregory HAMILTON ,  Guiling ZHAO ,  Huifen CHEN ,  Blake DANIELS ,  Craig STIVALA

IPC: C07D498/04 ,  A61P1/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/16 ,  A61P25/28 ,  C07D235/12 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D498/04 ,  A61P25/16 ,  A61P25/28 ,  C07D235/12 ,  C07D471/04 ,  C07D487/04 ,  A61P1/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00

Abstract: The invention provides novel compounds having the general formula I:




wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

公开(公告)号：US20240293829A1

公开(公告)日：2024-09-05

申请号：US18431838

申请日：2024-02-02

Applicant: Genentech, Inc.

Inventor： Nicholas RUMMEL ,  Patrick Daniel AHYOW

IPC: B04B7/00 ,  B33Y80/00 ,  C12M1/26

CPC classification number: B04B7/00 ,  B33Y80/00 ,  C12M33/10

Abstract: Provided herein are systems, devices and methods for harvesting biological cells with a centrifuge. A biological cell harvesting centrifuge apparatus may be provided with a rectangularly shaped base and 21 laterally spaced apart upright supports. Each upright support may extend vertically upward from the base and have a hollow core. Each upright support may be configured to slidably receive and support either one, two or four vertical edges of either one, two or four 15 mL micro bioreactor vessels. The 21 upright supports may be arranged in a 3×7 array such that they form a 2×6 array of receptacles configured to slidably receive and support 12 of the bioreactor vessels. The upright supports may be configured to support at least 80% of the vertical edges of the bioreactor vessels.

公开(公告)号：US12078638B2

公开(公告)日：2024-09-03

申请号：US17835418

申请日：2022-06-08

Applicant: Genentech, Inc.

Inventor： Priti Hegde ,  Mahrukh Huseni

IPC: C12Q1/6886 ,  A61K31/404 ,  A61K39/395 ,  A61K45/06 ,  A61P35/04 ,  C07K16/22 ,  C07K16/28 ,  G01N33/574 ,  A61K39/00

CPC classification number: G01N33/5748 ,  A61K31/404 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/04 ,  C07K16/22 ,  C07K16/2827 ,  C12Q1/6886 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)), lung cancer (e.g., non-small cell lung cancer (NSCLC)), bladder cancer (e.g., urothelial bladder cancer (UBC)), liver cancer (e.g., hepatocellular carcinoma (HCC)), ovarian cancer, or breast cancer (e.g., triple-negative breast cancer (TNBC))). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)), or with an angiogenesis inhibitor (e.g., a VEGF antagonist (e.g., a VEGFR inhibitor, (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib)))).

公开(公告)号：US20240288430A1

公开(公告)日：2024-08-29

申请号：US18513107

申请日：2023-11-17

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Craig Anthony CUMMINGS ,  Yan LI ,  Sarah Margaret SHAGAN ,  Erica Beth SCHLEIFMAN ,  David SHAMES ,  David FABRIZIO ,  Daniel LIEBER ,  Geoffrey Alan OTTO ,  Mark KENNEDY ,  Travis CLARK ,  Doron LIPSON ,  Jie HE ,  Shan ZHONG

IPC: G01N33/574 ,  A61K39/00 ,  A61P35/00 ,  C07K14/735 ,  C07K16/28 ,  C12Q1/68 ,  C12Q1/6883 ,  G06F16/28 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70

CPC classification number: G01N33/574 ,  A61P35/00 ,  C07K14/70535 ,  C07K16/2827 ,  C07K16/2896 ,  C12Q1/68 ,  C12Q1/6883 ,  G01N33/57492 ,  G06F16/285 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/24 ,  C12Q2600/156 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.